Results 211 to 220 of about 13,243,158 (348)
Nephrotic Syndrome as a Complication of Immune Tolerance in Hemophilia B [PDF]
, 1997 Bruce M. Ewenstein +7 more
openalex +1 more source
Clinical perspectives of emerging pathogens in bleeding disorders. [PDF]
, 2006 As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmissible viruses, and the incorporation of viral reduction processes during plasma fractionation, coagulation-factor concentrates (CFC) are now judged safe ...
Bozzette, Samuel +11 more
core +1 more source
Cancer Medicine, Volume 14, Issue 9, May 2025.A comprehensive outline of the study, detailing the process from DNA extraction to the evaluation of RB1 mutations in relation to clinical features and patient outcomes. ABSTRACT Background Retinoblastoma (Rb) is a rare intraocular malignancy that originates in the retina of children under 5 years of age.
Mohammad Faranoush +13 more
wiley +1 more source
Molecular diagnosis of hemophilia A and B. Report of five families from Costa Rica
Revista de Biología Tropical, 2004 Hemophilia Aand B are X-chromosome linked bleeding disorders caused by deficiency of the respective coagulation factor VIII and IX. Affected individuals develop a variable phenotype of hemorrhage caused by a broad range of mutations within the Factor ...
Lizbeth Salazar-Sánchez +8 more
doaj
Head &Neck, Volume 47, Issue 5, Page E50-E57, May 2025.ABSTRACT Background Infantile fibrosarcoma (IFS) is a rare pediatric tumor of intermediate malignancy with high local aggressiveness that typically presents in young infants. Its occurrence in the head and neck region is rare. Complete non‐mutilating surgical resection is often not possible, requiring multimodal treatment.
Teresa M. Cardesa‐Salzmann +14 more
wiley +1 more source
Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies [PDF]
, 2000 Acquired hemophilia, caused by autoantibodies against coagulation factor VIII, is usually treated with steroids, cyclophosphamide, intravenous gammaglobulins and sporadically other drugs.
Baele, Gaston +2 more
core
Tissue Engineering and Regenerative Medicine: Perspectives and Challenges
MedComm, Volume 6, Issue 5, May 2025.Tissue engineering and regenerative medicine. This review presents cell therapy, extracellular vesicle therapy, and tissue engineering in regenerative medicine, highlighting their key historical milestones, clinical applications, and current challenges.
Van T. Hoang +12 more
wiley +1 more source
Discussion:Future Considerations in the Management of Hemophilia B [PDF]
, 1995 openalex +1 more source
A Toolkit for Healthcare Transition for Adolescents With Classical Myeloproliferative Neoplasms
Pediatric Blood &Cancer, Volume 72, Issue 5, May 2025.ABSTRACT Classical myeloproliferative neoplasms (MPNs) are being identified more frequently in adolescents. There is no guidance on the healthcare transition of young MPN patients from pediatric to adult medicine. Therefore, we convened an international panel of experts in both pediatric and adult MPN care to develop three tools to facilitate high ...
Nicole Kucine +8 more
wiley +1 more source